Literature DB >> 25772492

Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.

Gabriel Castellanos1,2, María A Fernández-Seara1,2, Oswaldo Lorenzo-Betancor3,2, Sara Ortega-Cubero3,2, Marc Puigvert4, Javier Uranga5, Marta Vidorreta1, Jaione Irigoyen1,3,2,6, Elena Lorenzo3, Arrate Muñoz-Barrutia5,7, Carlos Ortiz-de-Solorzano5, Pau Pastor3,2,6,8, María A Pastor1,2,6.   

Abstract

BACKGROUND: We aimed to analyze the diagnostic accuracy of an automated segmentation and quantification method of the SNc and locus coeruleus (LC) volumes based on neuromelanin (NM)-sensitive MRI (NM-MRI) in patients with idiopathic (iPD) and monogenic (iPD) Parkinson's disease (PD).
METHODS: Thirty-six patients (23 idiopathic and 13 monogenic PARKIN or LRRK2 mutations) and 37 age-matched healthy controls underwent 3T-NM-MRI. SNc and LC volumetry were performed using fully automated multi-image atlas segmentation. The diagnostic performance to differentiate PD from controls was measured using the area under the curve (AUC) and likelihood ratios based on receiver operating characteristic (ROC) analyses.
RESULTS: We found a significant reduction of SNc and LC volumes in patients, when compared to controls. ROC analysis showed better diagnostic accuracy when using SNc volume than LC volume. Significant differences between ipsilateral and contralateral SNc volumes, in relation to the more clinically affected side, were found in patients with iPD (P = 0.007). Contralateral atrophy in the SNc showed the highest power to discriminate PD subjects from controls (AUC, 0.93-0.94; sensitivity, 91%-92%; specificity, 89%; positive likelihood ratio: 8.4-8.5; negative likelihood ratio: 0.09-0.1 at a single cut-off point). Interval likelihood ratios for contralateral SNc volume improved the diagnostic accuracy of volumetric measurements.
CONCLUSION: SNc and LC volumetry based on NM-MRI resulting from the automated segmentation and quantification technique can yield high diagnostic accuracy for differentiating PD from health and might be an unbiased disease biomarker.
© 2015 International Parkinson and Movement Disorder Society. © 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's; diagnosis; magnetic resonance imaging; neuromelanin; substantia nigra

Mesh:

Substances:

Year:  2015        PMID: 25772492     DOI: 10.1002/mds.26201

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  46 in total

1.  Clinical utility of visualisation of nigrosome-1 in patients with Parkinson's disease.

Authors:  Albert Stezin; Rajini M Naduthota; Ragasudha Botta; Shriram Varadharajan; Abhishek Lenka; Jitender Saini; Ravi Yadav; Pramod Kumar Pal
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  Bayesian framework inspired no-reference region-of-interest quality measure for brain MRI images.

Authors:  Michael Osadebey; Marius Pedersen; Douglas Arnold; Katrina Wendel-Mitoraj
Journal:  J Med Imaging (Bellingham)       Date:  2017-06-13

3.  Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI.

Authors:  Jason Langley; Daniel E Huddleston; Christine J Liu; Xiaoping Hu
Journal:  MAGMA       Date:  2016-09-29       Impact factor: 2.310

4.  Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis.

Authors:  Se Jin Cho; Yun Jung Bae; Jong-Min Kim; Donghyun Kim; Sung Hyun Baik; Leonard Sunwoo; Byung Se Choi; Jae Hyoung Kim
Journal:  Eur Radiol       Date:  2020-09-04       Impact factor: 5.315

Review 5.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

6.  Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease.

Authors:  Hiroto Takahashi; Yoshiyuki Watanabe; Hisashi Tanaka; Masahito Mihara; Hideki Mochizuki; Tian Liu; Yi Wang; Noriyuki Tomiyama
Journal:  Br J Radiol       Date:  2018-05-17       Impact factor: 3.039

7.  The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis.

Authors:  Xiangming Wang; Yuehui Zhang; Chen Zhu; Guangzong Li; Jie Kang; Fang Chen; Ling Yang
Journal:  Neurol Sci       Date:  2019-08-07       Impact factor: 3.307

Review 8.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

9.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

Review 10.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.